cyrilzakka/clinical-trials huggingface dataset:
Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection

Influence of antiviral treatment to the long term prognosis of patients with chronic HBV infection. The aim of antiviral treatment for HBV is to reduce the long term severe complications. In this study, the investigators divided patients with chronic HBV infection into two groups, which start early antiviral treatment and conventional antiviral treatment respectively. All the patients will be followed for ten years. From this study, the investigators want to find out the optimal time for patients with chronic HBV infection to start antiviral treatment.


Eligibility Criteria:
Inclusion Criteria:

* HBsAg positive for more than 6 months.
* HBeAg positive.
* HBV DNA over 10E5 copies/ml.

Exclusion Criteria:

* Previous antiviral treatment for HBV.
* Co infection of HIV, HCV, HEV, HAV, or HAV.
* Evidence of hepatic carcinoma.
* Evidence of autoimmune disease.
* Evidence of thyroid disease.
* History of mental sickness.
Optimizing Football Training: Integrating Portable Force Plates for Advanced Performance Analysis

Optimizing Football Training at Multan Sports Complex: Integrating Portable Force Plates for Advanced Performance Analysis," aims to enhance football training through innovative technology. Under the supervision of Dr. Junaid Gondal, this MS Rehabilitation Science project explores the use of portable force plates to provide real-time data on players' biomechanics, enabling personalized training programs that improve performance and reduce injury risks.

The research adopts a randomized control trial design, involving 30 male football players aged 18-35. Participants are divided into intervention and control groups, with the former using portable force plates during training. Data analysis will be conducted using IBM SPSS. This study underscores the significance of advanced performance analysis in football training, advocating for the integration of cutting-edge technology to refine training methods and enhance athletic performance at the Multan Sports Complex.

Eligibility Criteria:
Inclusion Criteria:

* Male football players at Multan Sports Complex
* aged 18-35
* willing to consent.

Exclusion Criteria:

* Female players
* unregistered players
* those with unstable medical conditions.
Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)

The purpose of the study is the identification of chromosomal aberrations in non-small cell lung cancer (NSCLC) .

The imaging system is intended for diagnostic use as an aid to the pathologist in the detection, counting and classifying ALK FISH stained lung samples.

The ALK Break Apart FISH test detects chromosomal aberrations via fluorescence in situ hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) tissue specimens. The FDA approved ALK kit is designed to detect rearrangements involving the ALK gene (2p23). Results from the ALK Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for the pathologist in the identification of patients eligible for treatment with XALKORI® (crizotinib).

Eligibility Criteria:
Inclusion Criteria:

* Well stained slides with bright FISH signals

Exclusion Criteria:

* Very old slides that were already bleached
At Home Placebo-controlled 8-week GOS Intervention on Emotion Behaviour and Cognition in Children (Age 6-14 Years).

This study aims to investigate how GOS food supplement influences the gut-microbiome-brain axis to improve emotion regulation skills and cognition in a sample of children and adolescents (aged 6-14 years).


Eligibility Criteria:
Inclusion Criteria:

* Typically developing, healthy male or female aged 6-14 years
* Access to home laptop/ personal computer

Exclusion Criteria:

* Current clinical levels of anxiety and/or co-morbid psychological diagnoses
* Neuro/developmental disorders
* Gastro-intestinal problems or disease
* Restrictive diets (e.g., lactose intolerance, gluten free)
Engagement in Physical Activities and Sports in Adolescents With Diaphragmatic Hernia

The objective is to understand how a population of adolescents - who have undergone diaphragm surgery within their first month of life (i.e. subjects who have been carriers of a rare impacting disease such as congenital diaphragmatic hernia (CDH)) - engages in physical and sports activities and what can be the hindering factors as well as the factors facilitating these practices.

Based on self-questionnaires and semi-structured interviews, this research is a qualitative research in the field of human and social sciences.

The qualitative survey will make it possible to report on the experience of the disease of children and parents; in parallel, a complete medical evaluation of the subjects (clinical and para-clinical) will be carried out.

The analysis of the verbatim of the self-questionnaires and interviews with regard to the real physical capacities of the subjects, will be discussed.


Eligibility Criteria:
Inclusion Criteria:

* Child/adolescent having undergone surgery for CDH in the first month of life, aged 12 to 18 years; absence of polypathology (i.e. diaphragmatic hernia not associated with another pathology); follow-up at the CDH reference centre, Lille site
* Written consent from both parents allowing the collection of data from the child/adolescent
* Written consent from the parent(s) agreeing to participate in the study by answering the questionnaires and the individual interview, for themselves and for their child
* Possibility of accessing equipment to conduct a video-conference interview if necessary.

Exclusion Criteria:

* Parents or child/adolescent not understanding French
* Parents under guardianship or child under legal protection
Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH)

The purpose of this study is to find risk factors for hemorrhagic stroke, specifically intracerebral hemorrhage (ICH), among Caucasians, African Americans, and Hispanics.


Eligibility Criteria:
Inclusion Criteria:

All cases must meet the following eligibility criteria:

1. Age 18 years or greater, fulfillment of the criteria for intracerebral hemorrhage
2. Resident for at least 6 months within 50 miles of the recruiting center
3. No evidence of trauma, vascular malformation or aneurysm, or brain tumor as a cause of the hemorrhage
4. Ability of the patient or legal representative to provide informed consent

Exclusion Criteria:

Exclusion Criteria:

1. Malignancies leading to coagulopathy
2. Hemorrhagic transformation of ischemic infarct
3. Hemorrhage secondary to dural venous sinus thrombosis
Assessment of Coeliac Disease in Patients With Type 2 Diabetes

This study aims to screen and diagnose coeliac disease in patients with type 2 diabetes and monitor the effect of gluten-free diet on the metabolic status

Coeliac Disease (CD) is a chronic disease with long-term consequences if untreated . CD has been traditionally associated with autoimmune disorders as type 1 Diabetes . However, recent data suggest association with insulin resistance, metabolic syndrome and type 2 diabetes . In a recent study comparing prevalence of autoimmune markers in type 1 diabetes versus type 2, coeliac disease serologic markers were 5% versus 8.7% respectively . In a study published at Nature communication, a genetic link between Ig A levels, type 2 diabetes, and coeliac disease was found . Gluten, among other factors, is thought to play a proinflammatory role exaggerating the damage to β-cells in both type 1 and type 2 diabetes . Presentation of coeliac disease is very variable, ranging from asymptomatic, gastrointestinal symptoms, atypical symptoms, to malabsorption syndrome. Our interest of the very wide atypical presentations is poorly controlled type 2 diabetes . Moreover, it has been recently suggested that gluten-free diet improves glucose metabolism . Screening and diagnosing coeliac disease remain a highly controversial topic, especially in individuals with atypical or no symptoms. A lifelong gluten avoidance can be only justified by a solid diagnosis, achieved by histopathological diagnosis. Intestinal biopsy is invasive test with not that-accurate results. The new guidelines confirmed the accuracy of the no-biopsy approach, only in case of high-titre positive two antibody tests, as published by the European Society Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHN) . However, guidelines intended for adults still insist on biopsy for confirming final diagnosis . The only exception is the interim guidance during Corona Virus -19 ( COVID-19 ) allowing non-biopsy diagnosis with two separate serology tests . However, recent retrospective study confirmed that high titre tTG had more than 95% diagnostic rate, and duodenal biopsy was not needed . For screening, many approaches have been studied, with measuring total immunoglobulin A (IgA) and IgA tissue transglutaminase (tTG) is the obvious first choice. However, for resource-deficient economies, rapid easy cheap point-of-care tests for deamidated gliadin antibodies (DGP) have been suggested .

Eligibility Criteria:
Inclusion Criteria:

1. adult patients ≥18 years old
2. diagnosed with type 2 diabetes mellitus

Exclusion Criteria:

1. Patients already diagnosed with co-morbid autoimmune disorder
2. patient diagnosed as systemic lupus
3. diagnosed as rheumatoid arthritis
4. already diagnosed with coeliac disease
Human Beta-defensin 1 in Vitiligo

There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.


Eligibility Criteria:
Inclusion Criteria:

* Patients with non-segmental vitiligo.
* Both genders.
* Age more than 18 years old.
* New cases or cases not receiving any treatment for at least 3 months prior to the study.

Exclusion Criteria:

* Universal or segmental vitiligo.
* Any contraindication to phototherapy treatment.
* History of autoimmune diseases or other systemic diseases.
* Any other skin disease.
Contingency Management of Psychostimulant Abuse in the Severely Mentally Ill

The purpose of this study is to determine the effectiveness of a behavioral treatment, contingency management, in reducing stimulant use in persons with serious mental illness.

This study will evaluate the efficacy of a twelve week contingency management (CM) intervention for treating psycho-stimulant substance abuse when delivered in the context of a community mental health center (CMHC) setting for adults suffering from serious mental illness (SMI). The CM paradigm to be used is one which has been shown effective in several recent large clinical trials, using the variable magnitude of reinforcement procedure. The reinforcers will be vouchers or actual items useful for day to day living in this population. Two hundred SMI participants with co-occurring stimulant disorders will be recruited from a large urban CMHC and randomized to receive either the active CM paradigm plus treatment as usual (TAU), or TAU which will include the delivery of reinforcement for study involvement (reinforcement that is not contingent on drug abstinence). The primary outcome is change in psycho-stimulant use (methamphetamine, amphetamine and/or cocaine). Secondary outcomes include: changes in use of other illegal drugs or alcohol; changes in CMHC treatment adherence and follow-through; changes in psychiatric symptoms, quality of life, and community outcomes (homelessness, incarcerations, etc.). Additional outcomes to be measured include changes in drug craving, stage of change, nicotine use, and HIV risk status. The study involves two phases, the 12 week treatment phase, where CM and control treatments are delivered, as well as a 3 month follow up phase.

Eligibility Criteria:
Inclusion Criteria:

* Enrolled patient at Community Psychiatric Clinic (CPC), a large mental health center in urban Seattle, Washington;
* Between 18 and 65 years of age;
* Diagnosis of of methamphetamine, amphetamine(illegal), or cocaine dependence or abuse;
* CPC medical record diagnosis of schizophrenia, schizoaffective disorder, bipolar I or II, or recurrent major depressive disorder
* Stimulant drug use one month before enrollment;
* Ability to understand written and spoken English;
* CPC clinical case manager must affirm the potential participant's ability to provide informed consent and clinical appropriateness (i.e., safety/severity of mental/substance/ physical health) to participate in the study.

Exclusion Criteria:

* Any medical/psychiatric condition, or severity of that condition, that, in the opinion of Dr. Ries, the PI, would compromise safe study participation
* Chart defined organic brain disorder or dementia;
* Current participation in a methadone maintenance program;
* Any other circumstances that in the PI's opinion precludes safe study participation.
Characterizing IgG4-RD With 68Ga-FAPI PET/CT

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as IgG4-related disease.And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research.Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of IgG4-related disease.

Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that is capable of affecting multiple organs. Common forms of presentation include:Type 1 (IgG4-related) autoimmune pancreatitis (AIP)，IgG4-related sclerosing cholangitis, major salivary gland enlargement or sclerosing sialadenitis; Orbital disease, often with proptosis and retroperitoneal fibrosis. The involved organs share a number of core pathologic features and striking clinical and serologic similarities, including tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and a variable degree of fibrosis that has a characteristic "storiform" pattern. 68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and it might be a pan-tumor PET agent. Recently we have reported a case of IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET/CT which showed FAPI was not more tumor-specific than FDG, furthermore,it might be more sensitive than FDG in detecting a certain type of inflammations-like the pancreatic lesion. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of IgG4-related disease.

Eligibility Criteria:
Inclusion Criteria:

* suspected or confirmed untreated IgG4-RD patients;
* 18F-FDG PET/CT within two weeks;
* signed written consent.

Exclusion Criteria:

* pregnancy;
* breastfeeding;
* known allergy against FAPI
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Bone Fragility Evaluation in Obese Patients

This research will study the bone fragility in obese patients, on DXA and CT-scan, in a transversal study. The investigators want also to study the specific risk factors of bone fragility in these obese patients (relationship between body composition on whole body on DXA, fat mass and its location, lean mass, weight loss after surgery and SBAC-L1), to improve the bone screening.


Eligibility Criteria:
Inclusion Criteria:

* patients followed at Nancy university hospital for a bariatric surgery
* CT-scan and DXA performed before surgery, with maximum 1 year before the 2 exams

Exclusion Criteria:

* \< 18 years
* Protected adults
Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA

This is a randomized, open-labelled, prospective 96-week study comparing the antiviral efficacy and safety of switching to entecavir 1 mg QD from lamivudine versus maintaining lamivudine 100 mg QD treatment in HBV-infected subjects currently receiving lamivudine monotherapy.

Entecavir has a higher potent antiviral efficacy and a lower drug resistance rate than Lamivudine in nucleoside-naïve CHB patients. The prompt switch from Lamivudine to Entecavir in patients who have insufficient hepatitis B virus suppression (HBV DNA ≥ 60 IU/mL by PCR) may lead to full viral suppression to undetectable level by PCR method. The prompt switch from Lamivudine to Entecavir in patients who have insufficient hepatitis B virus suppression (HBV DNA ≥ 60 IU/mL) may preclude development of drug resistance. The results of this study will provide a rationale for switch treatment from one antiviral to another one, especially from LAM to ETV.

Eligibility Criteria:
Inclusion Criteria:

* Adult subjects (18-70 years of age) currently taking lamivudine monotherapy for chronic HBV infection for at least 6 months with ≥ HBV DNA 60 IU/mL level and HBeAg positive at baseline.

Exclusion Criteria:

* All subjects will be tested for presence of M204V/I mutations in the YMDD motif at baseline. Subjects with M204V/I mutations in the YMDD motif at baseline are not eligible for the study.
* Subjects treated with other antiviral drugs (e.g. adefovir) in combination with lamivudine are not eligible for this study.
* Subjects should have ALT \< 10 x ULN, and no evidence of hepatocellular carcinoma.
* Subjects should be without serological evidence of co-infection with HCV, HIV, or HDV.
* Subjects with decompensated liver disease, as well as pregnant or breast-feeding women, will not be eligible for the study.
The Role of Bifidobacterium Intervention in Food Allergic Infants

Infant food protein allergy is the most common allergic disease in children, which can lead to infantile-specific dermatitis, intestinal inflammation, and so on. Dietary avoidance is a common strategy for food protein allergy in infants and young children. However, the hidden etiology of food protein allergy or multiple food allergies often leads to poor efficacy. The aim of this study is to observe the clinical effectiveness of Bifidobacterium intervention on food allergy.


Eligibility Criteria:
Inclusion Criteria:

* 0 -12 months infant
* Infants that are allergic (confirmed by an allergist) to at least one of the main food allergens (cow's milk, egg, soy or wheat) and is following an elimination diet to at least one of these allergens.

Exclusion Criteria:

* Patients had used probiotics within 1 month prior to the study
* Allergy or intolerance to probiotics or their excipient
* Serious primary diseases of the cardiovascular, nervous, respiratory,hepatobiliary immunology，and endocrine systems;
LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia

This study is designed to evaluate the safety, pharmacokinetics and preliminary efficacy of the anti-CD20 monoclonal antibody LFB-R603 in patients with relapsed or refractory B-cell chronic lymphocytic leukemia who have received at least one prior fludarabine-containing regimen.


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent
* Relapsed or refractory B-CLL after at least one prior course of therapy with fludarabine
* Circulating lymphocytes expressing CD20
* Peripheral blood lymphocyte count \> 5,000/µL
* ECOG performance status ≤ 2
* Life expectancy ≥ 3 months
* Negative blood pregnancy test before inclusion for women of childbearing potential
* Medically acceptable method of birth control throughout the study for women of childbearing potential
* Being considered as reliable and capable of adhering to the protocol and compliant with study procedures
* Covered by healthcare insurance

Exclusion Criteria:

* Transformation of CLL into a high grade lymphoma
* Allogeneic stem cell transplantation \< 6 months before enrolment
* Prior treatment with anti-CD20 monoclonal antibodies \< 6 months before enrolment
* Prior treatment with alemtuzumab \< 2 months before enrolment
* Treatment with any IMP or participation in a clinical study within 30 days prior to enrolment
* Known severe anaphylactic or other hypersensitivity reactions secondary to a prior exposure to murine antibodies or to any component of LFB-R603
* Patient with prior treatment or concomitant medication that may interfere with the interpretation of the study data
* Patient with a concomitant malignancy other than basal cell carcinoma of the skin, or in situ carcinoma of the cervix or the breast
* Patient with serious non-malignant disease, active infection requiring systemic antibiotic, antifungal or antiviral drug or physical examination or laboratory abnormalities, that would compromise protocol objectives
* Positive serology to HIV, HCV or presence of HBs Ag
* Creatinine clearance, calculated according to Cockroft -Gault formula \< 60 mL/min
* ALT and /or AST level \> 1.5 times the upper limit of normal
* Pregnancy or breastfeeding
To Determine if Sleep Deprivation Results in Increased Esophageal Acid Exposure

The purpose of this study is to determine if sleep deprivation results in increased esophageal acid exposure in healthy controls and gastroesophageal reflux disease (GERD) patients.

To determine if increased esophageal acid exposure is mediated by altering appetite regulation. To assess if there is any relationship between sleep deprivation and the serum level of TNF-alfa (a protein that can be elevated in inflammation).

Eligibility Criteria:
Inclusion Criteria:

* Male/Female - 18-80
* 2 or more episodes of heartburn a week for last 3 months

Exclusion Criteria:

* Previous upper GI surgery
* Underlying co-morbidity
* Narcotic medications
* Psychotropic's and Benzodiazapines medications
* Hx of psychological abnormalities
* Hx of ETOH in previous 6 mos.
* Diabetes Mellitus
* Neuropathy
* Seizures
* Sleep Apnea
* Co-morbidity that interfere w/sleep
* Women who are pregnant, or childbearing yrs, not on BC